Irving Weissman's decades of work isolating and characterising the haematopoietic stem cell (HSC) at the single-cell level provided molecular and functional markers that defined stem cell identity with unprecedented precision. His use of fluorescence-activated cell sorting (FACS) and transplantation assays established that HSCs could be purified to near-homogeneity and that a single HSC possessed sufficient capacity to reconstitute lifelong haematopoiesis in recipient mice. Weissman identified surface antigens (initially Thy-1 and Lin−, later CD34 in humans) that distinguish HSCs from their more-differentiated progeny, enabling enrichment and clinical isolation. These markers became instrumental in designing haematopoietic transplantation protocols and later in directing stem cell differentiation in culture. His work on cancer stem cells postulated that tumours arise from aberrant stem cells, a paradigm that reshaped oncology thinking and motivated new therapeutic strategies. Clinically, Weissman's HSC markers underpin mobilisation regimens and apheresis procedures used to harvest stem cells for transplantation, benefiting patients with haematologic malignancies and blood disorders. His rigorous single-cell approach established the standard for functional stem cell definition and demonstrated that pluripotent cells were not required for therapeutic utility—tissue-specific stem cells could be similarly powerful when properly characterised and applied.
Most clinical uses of stem cells remain investigational — check the evidence and approval status for your condition before acting on any clinic's claims.
Sources & profiles
← All pioneers · Conditions compared →